S
Sylvain Lamure
Researcher at University of Montpellier
Publications - 29
Citations - 552
Sylvain Lamure is an academic researcher from University of Montpellier. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 15 publications receiving 97 citations. Previous affiliations of Sylvain Lamure include Centre national de la recherche scientifique.
Papers
More filters
Journal ArticleDOI
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
Livio Pagano,Livio Pagano,Jon Salmanton-García,Francesco Marchesi,Alessandro Busca,Paolo Corradini,Martin Hoenigl,Martin Hoenigl,Nikolai Klimko,Philipp Koehler,Antonio Pagliuca,Francesco Passamonti,Luisa Verga,Benjamin Víšek,Osman Ilhan,Gianpaolo Nadali,Barbora Weinbergerova,Raúl Córdoba-Mascuñano,Monia Marchetti,Graham P. Collins,Francesca Farina,Chiara Cattaneo,Alba Cabirta,Maria Gomes-Silva,Federico Itri,Jaap van Doesum,Marie-Pierre Ledoux,Martin Čerňan,Ozren Jakšić,Rafael F. Duarte,Gabriele Magliano,Ali S. Omrani,Nicola Stefano Fracchiolla,Austin G. Kulasekararaj,Austin G. Kulasekararaj,Toni Valković,Christian Bjørn Poulsen,Marina Machado,Andreas Glenthøj,Igor Stoma,Zdeněk Ráčil,Klára Piukovics,Milan Navrátil,Ziad Emarah,Uluhan Sili,Johan Maertens,Ola Blennow,Rui Bergantim,Carolina García-Vidal,Lucia Prezioso,Anna Guidetti,Maria Ilaria Del Principe,Marina Popova,Nick de Jonge,Irati Ormazabal-Vélez,Noemí Fernández,Iker Falces-Romero,Annarosa Cuccaro,Stef Meers,Caterina Buquicchio,Darko Antic,Murtadha Al-Khabori,Ramón García-Sanz,Monika Biernat,Maria Chiara Tisi,Ertan Sal,Laman Rahimli,Natasa Colovic,Martin Schönlein,Maria Calbacho,Carlo Tascini,Carolina Miranda-Castillo,Nina Khanna,Gustavo-Adolfo Méndez,Verena Petzer,Jan Novák,Caroline Besson,Rémy Duléry,Sylvain Lamure,Marcio Nucci,Giovanni Zambrotta,Pavel Žák,Guldane Cengiz Seval,Valentina Bonuomo,Jiří Mayer,Alberto López-García,Maria Vittoria Sacchi,Stephen Booth,Fabio Ciceri,Margherita Oberti,Marco Salvini,Macarena Izuzquiza,Raquel Nunes-Rodrigues,Emanuele Ammatuna,Aleš Obr,Raoul Herbrecht,Lucía Núñez-Martín-Buitrago,Valentina Mancini,Hawraa M Shwaylia,Mariarita Sciumè,Jenna Essame,Marietta Nygaard,Josip Batinić,Josip Batinić,Yung Gonzaga,Isabel Regalado-Artamendi,Linda Katharina Karlsson,Maryia Shapetska,Michaela Hanakova,Shaimaa El-Ashwah,Zita Borbényi,Gökçe Melis Çolak,Anna Nordlander,Giulia Dragonetti,Giulia Dragonetti,Alessio Maria Edoardo Maraglino,Alessio Maria Edoardo Maraglino,Amelia Rinaldi,Cristina De Ramón-Sánchez,Oliver A Cornely +119 more
TL;DR: In this paper, the authors studied the risk factors for adverse outcomes in patients with hematological malignancies (HM) who developed COVID-19 and analyzed predictors of mortality.
Journal ArticleDOI
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.
Rémy Duléry,Sylvain Lamure,Marc Delord,Roberta Di Blasi,Adrien Chauchet,Thomas Hueso,Cédric Rossi,Bernard Drenou,Bénédicte Deau Fischer,Carole Soussain,Pierre Feugier,Nicolas Noel,Sylvain Choquet,Serge Bologna,Bertrand Joly,Laure Philippe,Milena Kohn,Sandra Malak,Guillemette Fouquet,Etienne Daguindau,Yassine Taoufik,Karine Lacombe,Guillaume Cartron,Catherine Thieblemont,Caroline Besson +24 more
Abstract: Prolonged Covid-19 is an emerging issue for patients with lymphoma or immune deficiency. We aimed to examine prolonged length of in-hospital stay (LOS) due to Covid-19 among patients with lymphoma and assess its determinants and outcomes. Adult patients with lymphoma admitted for Covid-19 to 16 French hospitals in March and April, 2020 were included. Length of in-hospital stay was analyzed as a competitor vs death. The study included 111 patients. The median age was 65 years (range, 19-92). Ninety-four patients (85%) had B-cell non-Hodgkin lymphoma. Within the 12 months prior to hospitalization for Covid-19, 79 patients (71%) were treated for their lymphoma. Among them, 63 (57%) received an anti-CD20 therapy. Fourteen patients (12%) had relapsed/refractory disease. The median LOS was 14 days (range, 1-235). After a median follow-up of 191 days (3-260), the 6-month overall survival was 69%. In multivariable analyses, recent administration of anti-CD20 therapy was associated with prolonged LOS (subdistribution hazard ratio 2.26, 95% confidence interval 1.42-3.6, p < 0.001) and higher risk of death (hazard ratio 2.17, 95% confidence interval 1.04-4.52, p = 0.039). An age ≥ 70 years and relapsed/refractory lymphoma were also associated with prolonged LOS and decreased overall survival. In conclusion, an age ≥ 70 years, a relapsed/refractory lymphoma and recent administration of anti-CD20 therapy are risk factors for prolonged LOS and death for lymphoma patients hospitalized for Covid-19. These findings may contribute to guide the management of lymphoma during the pandemic, support evaluating specific therapeutic approaches, and raise questions on the efficacy and timing of vaccination of this particular population.
Journal ArticleDOI
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study.
Sylvain Lamure,Remy Dulery,Roberta Di Blasi,Adrien Chauchet,Cécile Laureana,Bénédicte Deau-Fischer,Bernard Drenou,Carole Soussain,Cédric Rossi,Nicolas Noel,Sylvain Choquet,Serge Bologna,Bertrand Joly,Milena Kohn,Sandra Malak,Guillemette Fouquet,Etienne Daguindau,Sophie Bernard,Catherine Thieblemont,Guillaume Cartron,Karine Lacombe,Caroline Besson +21 more
TL;DR: The characteristics of patients with lymphoma hospitalized for Coronavirus Disease 2019 (Covid-19) and the determinants of mortality were described and survival of patients younger than 70 years without relapsed/refractory lymphoma was comparable to that of the general population.
Journal ArticleDOI
Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.
Catherine Belin,Perrine Devic,Xavier Ayrignac,Amélie Dos Santos,Adrien Paix,Lila Sirven-Villaros,Claire Simard,Sylvain Lamure,Thomas Gastinne,Renata Ursu,Colette Berger,Laura Platon,Benoit Tessoulin,Elie Azoulay,Florent Wallet,Catherine Thieblemont,Emmanuel Bachy,Guillaume Cartron,David Laplaud,Antoine F. Carpentier +19 more
TL;DR: The clinical pattern is heterogeneous but cognitive disorders (not limited to language disorders) and, to a minor degree, non-pyramidal motor disorders, appeared as a signature of severe neurotoxicity.
Journal ArticleDOI
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
Thomas Hueso,Anne-Sophie Godron,Emilie Lanoy,Jérôme Pacanowski,L. Levi,Emmanuel Gras,Laure Surgers,A. Guemriche,Jean-Luc Meynard,F. Pirenne,S. Idri,Pierre Tiberghien,Pascal Morel,Caroline Besson,Remy Dulery,Sylvain Lamure,Olivier Hermine,Amandine Gagneux-Brunon,Nathalie Freymond,Sophie Grabar,Karine Lacombe +20 more
TL;DR: In this paper , the effect of COVID-19 convalescent plasma (CCP) therapy appears as a promising approach through the transfer of neutralizing antibodies specific to SARS-CoV-2.